The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for moderate-to-severe AD, adding a costly new dynamic to a treatment landscape hitherto entrenched with largely generic topical agents and systemic immunosuppressants. With IL-13 inhibitor tralokinumab (AstraZeneca/Leo Pharma), JAK inhibitor abrocitinib (Pfizer), and PDE-4 inhibitor Eucrisa (Pfizer) poised to further revolutionize the traditionally low-cost AD market, this research explores the evolving reimbursement and uptake environment in France, Germany, Italy, Spain, and the UK as payers and prescribers strive to balance clinical need with substantial budgetary constraints.
- What are current prescribing practices for AD in each of the top 5 European markets? How is the impact of payer policy on prescribing evolving following the approval of Dupixent?
- How do prescribing patterns differ between the countries under study? How do coverage constraints rank against other market access hurdles for key drugs?
- How do payers view promising but costly emerging targeted agents? What are the key HTA considerations and P&R drivers? What key access challenges will these therapies face?
- How do prescribers perceive emerging AD therapies? How do they expect the launch of these therapies to impact prescribing? What uptake hurdles do they foresee?
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers examining reimbursement dynamics and evaluating the impact of payer policy on prescribing behavior.
France, Germany, Italy, Spain, United Kingdom
- Survey of 250 dermatologists across the top 5 European markets (50 per country)
- Interviews with 10 payers across the top 5 European markets (2 per country)
KEY DRUGS COVERED
Prescription topical corticosteroids, topical calcineurin inhibitors, conventional systemic treatments, Dupixent, tralokinumab, abrocitinib, Eucrisa
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Pricing and reimbursement dynamics
- Impact of payer policy and coverage on prescribing
- Market access outlook for emerging therapies
- Atopic Dermatitis/Atopic Eczema - Access & Reimbursement - Detailed, Expanded Analysis (EU) Top 5 European Markets
- Access & Reimbursement - Atopic Dermatitis - Top 5 European Markets - August 2019
Author(s): Micaela Vidal-Taylor; Ritesh Gupta, Ph.D.
Micaela Vidal-Taylor is an Analyst in the Global Market Access team at DRG, with a particular focus on the EU5. In this role, she produces primary and secondary research-based reports and other insights designed for decision markets within the biopharmaceutical industry. Micaela holds a PhD in Clinical Medicine from Imperial College London, for which she received a full scholarship from the British Heart Foundation. She also holds a masters degree in Biomedical Sciences from Imperial College London in which she achieved a Distinction, and a masters degree in Pharmacology from the University of Oxford.
Ritesh is a manager in the Immune and Inflammatory Disorders team at DRG, part of Clarivate. He has years of experience in competitive intelligence, scientific analysis, and market opportunity assessment and has worked in various therapeutic areas to provide strategic recommendations to pharmaceutical companies. He holds a Ph.D. in cell biology from the Max Delbrück Center for Molecular Medicine in Berlin.